Located in the Quartiere San Lorenzo, the Policlinico Umberto I of Rome is the polyclinic of the Faculty of Medicine and Surgery of the Sapienza Università di Roma.

During the past decade, Policlinico Umberto I - Universita La Sapienza conducted 56 clinical trials. In the 10-year time frame, 56 clinical trials started and 20 clinical trials were completed, i.e. on average, 35.7% percent of trials that started reached the finish line to date. In the past 5 years, 27 clinical trials started and 16 clinical trials were completed. i.e. 59.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Policlinico Umberto I - Universita La Sapienza" #1 sponsor was "Eli Lilly and Company" with 5 trials, followed by "Hoffmann-La Roche" with 5 trials sponsored, "Mario Negri Institute for Pharmacological Research" with 5 trials sponsored, "Shire" with 5 trials sponsored and "University of Roma La Sapienza" with 5 trials sponsored. Other sponsors include 42 different institutions and companies that sponsored additional 39 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Policlinico Umberto I - Universita La Sapienza" #1 collaborator was "ALS Association" with 1 trials as a collaborator, "Azienda Policlinico Umberto I" with 1 trials as a collaborator, "Baxalta Innovations GmbH, now part of Shire" with 1 trials as a collaborator, "Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte" with 1 trials as a collaborator and "European Network of Individualized Treatment in Endometrial Cancer - ENITEC" with 1 trials as a collaborator. Other collaborators include 8 different institutions and companies that were collaborators in the rest 18 trials.

According to Clinical.Site data, the most researched conditions in "Policlinico Umberto I - Universita La Sapienza" are "Multiple Myeloma" (5 trials), "Alzheimer's Disease" (4 trials), "Crohn's Disease" (4 trials), "Hepatitis B, Chronic" (3 trials) and "Ulcerative Colitis" (3 trials). Many other conditions were trialed in "Policlinico Umberto I - Universita La Sapienza" in a lesser frequency.

Most popular intervention types in "Policlinico Umberto I - Universita La Sapienza" are "Drug" (53 trials), "Other" (7 trials), "Biological" (4 trials), "Device" (2 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (19 trials), "Dexamethasone" (4 trials), "JNJ-73763989" (4 trials), "Ontamalimab" (4 trials) and "Gantenerumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Policlinico Umberto I - Universita La Sapienza" are 65 trials for "All" genders, 6 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Policlinico Umberto I - Universita La Sapienza". undefined are not yet recruiting, 15 are recruiting, 13 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 28 completed trials in Policlinico Umberto I - Universita La Sapienza, undefined suspended trials, and 11 terminated clinical trials to date.

Out of the total trials that were conducted in Policlinico Umberto I - Universita La Sapienza, 0 "Phase 1" clinical trials were conducted, 16 "Phase 2" clinical trials and 34 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 2 trials that are defined as “Not Applicable".